Fresenius Kabi Pharmaceuticals Holding, Inc. (Fresenius Kabi Pharmaceuticals) is an integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products. The Company primarily focuses on the injectable oncology, anti-infective, anesthetic/analgesic and critical care markets. The Company manufactures products in each of the three basic forms in which injectable products are sold: liquid, powder and lyophilized, or freeze-dried. Its products are generally used in hospitals, long-term care facilities, alternate care sites and clinics within North America. As of December 31, 2009, the Company had over 30 abbreviated new drug applications (ANDAs) pending with the United States Food and Drug Administration (FDA) and over 70 product candidates under development across its oncology, anti-infective and critical care product categories.
APP Pharmaceuticals, Inc., a subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced that it has entered into a commercialization, manufacture and supply agreement with Teva Pharmaceutical USA, Inc., a subsidiary of Teva Pharmaceutical Industries,
* Teva to buy Peruvian generics maker (Adds details, updates share movement)
Jan 26 (Reuters) - Teva Pharmaceutical Industries (TEVA.O) (TEVA.TA) and a unit of Fresenius Kabi Pharmaceuticals Holding APCVZ.O agreed to manufacture and market a generic version of Eli Lilly and Co's (LLY.N) chemotherapy drug Gemzar, sending Teva's shares up 5 percent.Search Amazon.com for iphone 4
